Literature DB >> 1516947

Endothelin-1 augments pressor response to angiotensin II infusion in rats.

K Yoshida1, M Yasujima, M Kohzuki, M Kanazawa, K Yoshinaga, K Abe.   

Abstract

To assess possible roles of endothelin in the regulation of blood pressure, we studied effects of a subpressor dose of endothelin-1 (3 micrograms/kg/day) on chronic blood pressure responses to infusion of angiotensin II and norepinephrine in rats. Rats were infused with angiotensin II at a subpressor dose (400 micrograms/kg/day i.p.) or with norepinephrine at a subpressor dose (360 micrograms/kg/day i.p.) for 6 days. Systolic blood pressure was significantly elevated during combined infusion of endothelin-1 and angiotensin II, whereas endothelin-1 alone or angiotensin II alone failed to induce any significant changes in systolic blood pressure compared with vehicle alone. This effect was sustained for the whole experimental period and was not associated with any significant changes in body weight, fluid intake, urine volume, or urinary electrolyte excretion. In contrast, combined infusion of endothelin-1 and norepinephrine failed to elevate systolic blood pressure, and no significant difference in systolic blood pressure was observed for the whole experimental period among the four groups of rats with endothelin-1 in combination with norepinephrine, endothelin-1 alone, norepinephrine alone, and vehicle alone. The present results indicate that angiotensin II and endothelin-1, but not norepinephrine and endothelin-1, work synergistically to raise the blood pressure and also suggest the possibility that endothelin-1 may modulate blood pressure control.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516947     DOI: 10.1161/01.hyp.20.3.292

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Endothelin mediates some of the renal actions of acutely administered angiotensin II.

Authors:  A Riggleman; J Harvey; C Baylis
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

5.  Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats.

Authors:  L T Tran; K M MacLeod; J H McNeill
Journal:  Mol Cell Biochem       Date:  2009-01-13       Impact factor: 3.396

8.  Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

Authors:  Li Yao; Hiroyuki Kobori; Matlubur Rahman; Dale M Seth; Takatomi Shokoji; Yuyan Fan; Guo-Xing Zhang; Shoji Kimura; Youichi Abe; Akira Nishiyama
Journal:  Hypertens Res       Date:  2004-07       Impact factor: 3.872

9.  Sex-Specific Effect of Endothelin in the Blood Pressure Response to Acute Angiotensin II in Growth-Restricted Rats.

Authors:  Suttira Intapad; Norma B Ojeda; Elliott Varney; Thomas P Royals; Barbara T Alexander
Journal:  Hypertension       Date:  2015-10-12       Impact factor: 10.190

10.  Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin-deficient, genetically hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.